Astellas Pharma Key Executives
This section highlights Astellas Pharma's key executives, including their titles and compensation details.
Find Contacts at Astellas Pharma
(Showing 0 of )
Astellas Pharma Earnings
This section highlights Astellas Pharma's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Date:
April 23, 2025
Time:
Before Market
Est. EPS:
$-
Status:
Unconfirmed
Last Earnings Results
Date:
February 03, 2025
EPS:
$-54.55
Est. EPS:
$18.94
Revenue:
$517.41B
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q3 | 2024 | 2025-02-08 | N/A | N/A |
| Read Transcript | Q2 | 2024 | 2024-10-31 | N/A | N/A |
| Read Transcript | Q1 | 2024 | 2024-08-03 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2024-04-26 | N/A | N/A |
| Read Transcript | Q3 | 2023 | 2024-02-05 | $15.30 | $10.40 |
| Read Transcript | Q2 | 2023 | 2023-11-02 | N/A | N/A |
| Read Transcript | Q1 | 2023 | 2022-08-01 | $23.28 | $13.60 |
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Healthcare
Drug Manufacturers - General
$1511.00
Stock Price
$2.70T
Market Cap
-
Employees
Tokyo, None
Location
Financial Statements
Access annual & quarterly financial statements for Astellas Pharma, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $1.60T | $1.52T | $1.30T | $1.25T | $1.30T |
| Cost of Revenue | $292.49B | $288.35B | $253.01B | $246.06B | $276.74B |
| Gross Profit | $1.31T | $1.23T | $1.04T | $1.00T | $1.02T |
| Gross Profit Ratio | 81.76% | 81.01% | 80.50% | 80.31% | 78.73% |
| Research and Development Expenses | $294.19B | $276.13B | $246.01B | $224.49B | $224.23B |
| General and Administrative Expenses | $740.11B | $630.27B | $548.84B | $504.32B | $499.30B |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $740.11B | $630.27B | $548.84B | $504.32B | $499.30B |
| Other Expenses | $251.37B | $- | $117.34B | $139.09B | $54.93B |
| Operating Expenses | $1.29T | $1.10T | $912.19B | $867.89B | $778.45B |
| Cost and Expenses | $1.43T | $1.39T | $1.17T | $1.11T | $1.06T |
| Interest Income | $11.46B | $8.11B | $6.15B | $11.61B | $4.36B |
| Interest Expense | $9.37B | $8.78B | $4.95B | $2.33B | $3.00B |
| Depreciation and Amortization | $157.84B | $105.74B | $79.68B | $72.65B | $66.40B |
| EBITDA | $195.34B | $240.46B | $241.03B | $219.83B | $316.41B |
| EBITDA Ratio | 12.18% | 16.24% | 16.76% | 17.63% | 24.20% |
| Operating Income | $124.61B | $133.03B | $155.69B | $136.05B | $243.99B |
| Operating Income Ratio | 7.77% | 8.76% | 12.01% | 10.89% | 18.76% |
| Total Other Income Expenses Net | $-99.64B | $-668.00M | $1.20B | $8.79B | $1.36B |
| Income Before Tax | $24.97B | $132.36B | $156.89B | $145.32B | $245.35B |
| Income Before Tax Ratio | 1.56% | 8.72% | 12.10% | 11.63% | 18.86% |
| Income Tax Expense | $7.92B | $33.65B | $32.80B | $24.73B | $49.94B |
| Net Income | $17.05B | $98.71B | $124.09B | $120.59B | $195.41B |
| Net Income Ratio | 1.06% | 6.50% | 9.57% | 9.65% | 15.02% |
| EPS | $9.50 | $54.24 | $67.08 | $64.93 | $104.15 |
| EPS Diluted | $9.47 | $54.09 | $67.05 | $64.90 | $104.08 |
| Weighted Average Shares Outstanding | 1.79B | 1.82B | 1.85B | 1.86B | 1.88B |
| Weighted Average Shares Outstanding Diluted | 1.80B | 1.83B | 1.85B | 1.86B | 1.88B |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $517.41B | $462.50B | $473.12B | $414.60B | $421.93B | $392.15B | $374.99B | $354.25B | $402.18B | $380.39B | $381.79B | $303.87B | $340.63B | $325.52B | $326.14B | $308.62B | $325.43B | $308.51B | $306.97B | $312.31B |
| Cost of Revenue | $98.52B | $116.93B | $91.14B | $105.88B | $75.90B | $74.41B | $68.95B | $62.28B | $74.42B | $62.78B | $88.87B | $58.91B | $69.36B | $62.50B | $62.23B | $58.33B | $68.19B | $59.90B | $59.65B | $55.10B |
| Gross Profit | $418.88B | $345.57B | $381.99B | $308.73B | $346.04B | $317.74B | $306.04B | $291.97B | $327.76B | $317.61B | $292.92B | $244.96B | $271.27B | $263.02B | $263.91B | $250.29B | $257.24B | $248.62B | $247.31B | $257.21B |
| Gross Profit Ratio | 80.96% | 74.70% | 80.70% | 74.50% | 82.00% | 81.00% | 81.60% | 82.40% | 81.50% | 83.50% | 76.70% | 80.60% | 79.60% | 80.80% | 80.90% | 81.10% | 79.05% | 80.59% | 80.57% | 82.36% |
| Research and Development Expenses | $79.09B | $85.51B | $86.82B | $77.85B | $74.39B | $77.36B | $64.59B | $70.08B | $66.88B | $65.17B | $74.01B | $68.36B | $58.59B | $60.75B | $58.31B | $55.67B | $57.12B | $54.41B | $57.29B | $64.47B |
| General and Administrative Expenses | $- | $- | $- | $193.15B | $199.50B | $179.28B | $168.18B | $159.29B | $163.02B | $154.56B | $153.40B | $142.42B | $135.91B | $133.40B | $137.11B | $141.27B | $120.91B | $121.36B | $120.78B | $145.72B |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $225.31B | $199.53B | $206.88B | $193.15B | $199.50B | $179.28B | $168.18B | $159.29B | $163.02B | $154.56B | $153.40B | $142.42B | $135.91B | $133.40B | $137.11B | $141.27B | $120.91B | $121.36B | $120.78B | $145.72B |
| Other Expenses | $230.68B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $32.89B | $46.42B | $23.42B | $14.81B | $32.69B | $77.52B | $6.62B | $46.54B | $8.41B | $41.20B |
| Operating Expenses | $535.08B | $285.04B | $331.33B | $271.00B | $327.17B | $320.95B | $260.99B | $340.12B | $266.00B | $232.30B | $260.29B | $257.20B | $217.92B | $208.96B | $228.12B | $274.46B | $184.65B | $222.31B | $186.47B | $251.40B |
| Cost and Expenses | $633.60B | $399.33B | $422.47B | $376.88B | $403.06B | $395.37B | $329.94B | $402.40B | $340.42B | $295.08B | $349.16B | $316.12B | $287.28B | $271.46B | $290.35B | $332.78B | $252.83B | $282.21B | $246.13B | $306.49B |
| Interest Income | $2.06B | $541.00M | $4.33B | $4.12B | $1.18B | $2.37B | $3.78B | $2.44B | $1.17B | $3.56B | $927.00M | $3.84B | $417.00M | $432.00M | $1.46B | $5.10B | $3.06B | $3.07B | $379.00M | $532.00M |
| Interest Expense | $4.23B | $5.05B | $4.50B | $4.19B | $2.83B | $2.27B | $2.72B | $2.07B | $2.80B | $1.51B | $2.40B | $675.00M | $1.30B | $1.25B | $1.72B | $589.00M | $520.00M | $271.00M | $956.00M | $700.00M |
| Depreciation and Amortization | $51.16B | $50.02B | $50.27B | $48.64B | $46.98B | $38.97B | $23.24B | $23.02B | $23.00B | $22.85B | $36.87B | $21.08B | $21.52B | $18.94B | $18.14B | $18.56B | $18.15B | $17.94B | $18.00B | $18.10B |
| EBITDA | $126.06B | $94.09B | $103.33B | $6.87B | $67.35B | $47.49B | $72.13B | $-22.68B | $85.96B | $111.73B | $70.60B | $12.78B | $99.42B | $73.43B | $55.40B | $-496.00M | $93.81B | $47.07B | $79.19B | $24.97B |
| EBITDA Ratio | 24.36% | 20.34% | 21.89% | 20.83% | 15.83% | 9.49% | 19.40% | -6.43% | 21.26% | 29.75% | 18.54% | 3.67% | 22.61% | 22.56% | 17.08% | 0.08% | 28.83% | 15.26% | 25.80% | 7.99% |
| Operating Income | $-116.19B | $60.53B | $53.32B | $37.72B | $18.96B | $5.22B | $45.79B | $-48.25B | $61.39B | $86.74B | $33.15B | $-13.69B | $79.20B | $54.08B | $36.09B | $-23.42B | $72.60B | $26.06B | $60.81B | $6.33B |
| Operating Income Ratio | -22.46% | 13.09% | 11.27% | 9.10% | 4.49% | 1.33% | 12.21% | -13.62% | 15.26% | 22.80% | 8.68% | -4.50% | 23.25% | 16.61% | 11.07% | -7.59% | 22.31% | 8.45% | 19.81% | 2.03% |
| Total Other Income Expenses Net | $-2.17B | $-21.50B | $-2.82B | $-86.39B | $-1.65B | $4.41B | $1.06B | $373.00M | $-1.63B | $628.00M | $-949.00M | $3.17B | $-2.61B | $-809.00M | $-259.00M | $4.51B | $2.54B | $2.55B | $-603.00M | $-168.00M |
| Income Before Tax | $-118.36B | $39.03B | $50.49B | $-45.96B | $17.31B | $5.33B | $46.85B | $-47.88B | $59.76B | $88.80B | $31.68B | $-10.52B | $78.32B | $53.26B | $35.83B | $-18.90B | $75.14B | $28.85B | $60.24B | $6.17B |
| Income Before Tax Ratio | -22.88% | 8.44% | 10.67% | -11.08% | 4.10% | 1.36% | 12.49% | -13.51% | 14.86% | 23.34% | 8.30% | -3.46% | 22.99% | 16.36% | 10.99% | -6.12% | 23.09% | 9.35% | 19.62% | 1.97% |
| Income Tax Expense | $-20.70B | $2.64B | $12.89B | $-15.38B | $2.80B | $6.79B | $13.72B | $-1.75B | $11.35B | $17.18B | $6.87B | $-2.11B | $17.43B | $12.33B | $5.14B | $-6.58B | $15.06B | $6.43B | $9.82B | $775.00M |
| Net Income | $-97.66B | $35.91B | $37.60B | $-33.28B | $14.51B | $-1.46B | $33.13B | $-46.12B | $48.41B | $71.62B | $24.81B | $-8.41B | $60.88B | $40.92B | $30.69B | $-12.33B | $60.08B | $22.43B | $50.41B | $5.39B |
| Net Income Ratio | -18.87% | 7.76% | 7.95% | -8.03% | 3.44% | -0.37% | 8.83% | -13.02% | 12.04% | 18.83% | 6.50% | -2.77% | 17.87% | 12.57% | 9.41% | -3.99% | 18.46% | 7.27% | 16.42% | 1.73% |
| EPS | $-54.57 | $19.94 | $21.00 | $-18.39 | $8.09 | $-0.81 | $18.46 | $-25.49 | $26.56 | $39.30 | $13.60 | $-4.57 | $32.86 | $22.09 | $16.56 | $-6.64 | $32.34 | $12.07 | $27.14 | $2.87 |
| EPS Diluted | $-54.57 | $19.94 | $20.94 | $-18.21 | $8.06 | $-0.81 | $18.42 | $-25.49 | $26.55 | $39.28 | $13.59 | $-4.57 | $32.84 | $22.08 | $16.55 | $-6.64 | $32.33 | $12.07 | $27.12 | $2.87 |
| Weighted Average Shares Outstanding | 1.79B | 1.80B | 1.80B | 1.81B | 1.79B | 1.79B | 1.79B | 1.81B | 1.82B | 1.82B | 1.83B | 1.84B | 1.85B | 1.85B | 1.85B | 1.86B | 1.86B | 1.86B | 1.86B | 1.86B |
| Weighted Average Shares Outstanding Diluted | 1.79B | 1.80B | 1.80B | 1.83B | 1.80B | 1.79B | 1.80B | 1.81B | 1.82B | 1.82B | 1.83B | 1.84B | 1.85B | 1.85B | 1.85B | 1.86B | 1.86B | 1.86B | 1.86B | 1.87B |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $335.69B | $376.84B | $315.99B | $326.13B | $318.39B |
| Short Term Investments | $- | $19.78B | $21.30B | $5.56B | $9.46B |
| Cash and Short Term Investments | $335.69B | $396.62B | $337.28B | $331.69B | $327.85B |
| Net Receivables | $548.04B | $427.96B | $382.46B | $343.18B | $347.04B |
| Inventory | $248.74B | $174.39B | $153.07B | $164.08B | $151.02B |
| Other Current Assets | $62.27B | $50.98B | $50.54B | $33.64B | $41.60B |
| Total Current Assets | $1.19T | $1.05T | $923.35B | $872.59B | $867.51B |
| Property Plant Equipment Net | $293.74B | $286.46B | $269.04B | $264.62B | $268.60B |
| Goodwill | $418.69B | $328.41B | $303.03B | $284.01B | $267.51B |
| Intangible Assets | $1.45T | $562.50B | $623.43B | $651.43B | $738.51B |
| Goodwill and Intangible Assets | $1.87T | $890.91B | $926.46B | $935.44B | $1.01T |
| Long Term Investments | $144.42B | $145.03B | $141.21B | $146.80B | $123.15B |
| Tax Assets | $45.59B | $84.17B | $72.33B | $54.18B | $52.88B |
| Other Non-Current Assets | $18.60B | $1.00M | $-1.00M | $-1.00M | $-1.00M |
| Total Non-Current Assets | $2.37T | $1.41T | $1.41T | $1.40T | $1.45T |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $3.57T | $2.46T | $2.33T | $2.27T | $2.32T |
| Account Payables | $185.19B | $140.24B | $130.74B | $124.78B | $171.95B |
| Short Term Debt | $472.28B | $75.00B | $- | $- | $344.11B |
| Tax Payables | $38.52B | $5.14B | $32.39B | $8.39B | $4.01B |
| Deferred Revenue | $- | $-88.55B | $-157.73B | $-136.10B | $11.70B |
| Other Current Liabilities | $589.74B | $505.66B | $524.28B | $459.20B | $266.94B |
| Total Current Liabilities | $1.29T | $726.03B | $687.41B | $592.37B | $798.71B |
| Long Term Debt | $518.49B | $-9.82B | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $121.28B | $138.94B | $163.80B | $173.48B |
| Deferred Tax Liabilities Non-Current | $51.35B | $6.05B | $5.82B | $18.16B | $27.66B |
| Other Non-Current Liabilities | $118.05B | $45.20B | $39.91B | $113.18B | $56.80B |
| Total Non-Current Liabilities | $687.89B | $222.53B | $184.68B | $295.14B | $230.28B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $1.97T | $948.56B | $872.09B | $887.51B | $1.03T |
| Preferred Stock | $- | $1.17T | $1.21T | $1.22T | $1.18T |
| Common Stock | $103.00B | $103.00B | $103.00B | $103.00B | $103.00B |
| Retained Earnings | $809.40B | $908.16B | $944.26B | $953.29B | $905.85B |
| Accumulated Other Comprehensive Income Loss | $533.30B | $340.64B | $247.51B | $167.37B | $109.99B |
| Other Total Stockholders Equity | $150.29B | $156.16B | $165.53B | $162.45B | $170.33B |
| Total Stockholders Equity | $1.60T | $1.51T | $1.46T | $1.39T | $1.29T |
| Total Equity | $1.60T | $1.51T | $1.46T | $1.39T | $1.29T |
| Total Liabilities and Stockholders Equity | $3.57T | $2.46T | $2.33T | $2.27T | $2.32T |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $3.57T | $2.46T | $2.33T | $2.27T | $2.32T |
| Total Investments | $144.42B | $110.58B | $101.88B | $102.97B | $78.96B |
| Total Debt | $1.01T | $200.01B | $212.74B | $278.26B | $413.33B |
| Net Debt | $670.03B | $-176.83B | $-103.24B | $-47.86B | $94.94B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $179.87B | $292.99B | $302.93B | $335.69B | $253.98B | $333.99B | $561.49B | $376.84B | $381.82B | $361.07B | $313.01B | $315.99B | $350.21B | $318.30B | $301.92B | $326.13B | $306.51B | $286.73B | $239.93B | $318.39B |
| Short Term Investments | $- | $- | $- | $28.78B | $31.46B | $29.66B | $41.33B | $19.78B | $31.48B | $31.95B | $23.75B | $21.30B | $17.88B | $9.99B | $4.08B | $5.56B | $19.97B | $7.70B | $4.59B | $9.46B |
| Cash and Short Term Investments | $179.87B | $292.99B | $302.93B | $335.69B | $285.44B | $363.65B | $602.81B | $396.62B | $413.30B | $393.02B | $336.76B | $337.28B | $368.09B | $328.29B | $306.00B | $331.69B | $326.48B | $294.44B | $244.52B | $327.85B |
| Net Receivables | $644.63B | $570.89B | $587.67B | $534.99B | $495.96B | $487.89B | $462.50B | $427.96B | $451.27B | $452.49B | $438.41B | $382.46B | $373.92B | $357.80B | $364.23B | $343.18B | $345.61B | $332.73B | $360.72B | $347.04B |
| Inventory | $287.34B | $260.21B | $256.05B | $248.74B | $225.98B | $213.65B | $200.22B | $174.39B | $163.22B | $168.64B | $164.83B | $153.07B | $151.58B | $148.73B | $157.25B | $164.08B | $155.74B | $155.74B | $155.07B | $151.02B |
| Other Current Assets | $92.07B | $78.91B | $94.02B | $75.32B | $42.73B | $51.57B | $51.91B | $50.98B | $44.80B | $45.00B | $49.28B | $50.54B | $45.74B | $41.63B | $41.23B | $33.64B | $35.47B | $36.99B | $35.66B | $41.60B |
| Total Current Assets | $1.20T | $1.20T | $1.24T | $1.19T | $1.05T | $1.12T | $1.32T | $1.05T | $1.07T | $1.06T | $989.28B | $923.35B | $939.33B | $876.45B | $868.72B | $872.59B | $863.29B | $819.90B | $795.98B | $867.51B |
| Property Plant Equipment Net | $332.72B | $315.35B | $309.69B | $293.74B | $289.03B | $296.56B | $290.78B | $286.46B | $269.11B | $280.55B | $280.18B | $269.04B | $267.82B | $266.67B | $269.70B | $264.62B | $255.18B | $265.67B | $267.11B | $268.60B |
| Goodwill | $432.80B | $399.44B | $443.67B | $418.69B | $387.97B | $403.82B | $355.68B | $328.41B | $324.07B | $353.10B | $334.26B | $303.03B | $293.65B | $284.99B | $284.11B | $284.01B | $267.80B | $273.39B | $276.87B | $267.51B |
| Intangible Assets | $1.21T | $1.32T | $1.50T | $1.45T | $1.45T | $1.53T | $590.42B | $562.50B | $616.54B | $653.63B | $639.83B | $623.43B | $652.25B | $640.98B | $630.32B | $651.43B | $697.16B | $687.31B | $729.40B | $738.51B |
| Goodwill and Intangible Assets | $1.64T | $1.72T | $1.95T | $1.87T | $1.84T | $1.94T | $946.11B | $890.91B | $940.61B | $1.01T | $974.09B | $926.46B | $945.90B | $925.97B | $914.44B | $935.44B | $964.96B | $960.70B | $1.01T | $1.01T |
| Long Term Investments | $19.15B | $143.12B | $19.48B | $144.42B | $85.75B | $88.98B | $142.97B | $90.79B | $71.22B | $70.32B | $146.19B | $141.21B | $144.74B | $137.32B | $95.50B | $97.41B | $98.04B | $83.59B | $82.28B | $69.50B |
| Tax Assets | $- | $53.17B | $54.18B | $45.59B | $42.62B | $44.28B | $100.64B | $84.17B | $93.22B | $96.46B | $92.10B | $72.33B | $58.46B | $55.09B | $54.56B | $54.18B | $51.51B | $55.23B | $55.49B | $52.88B |
| Other Non-Current Assets | $251.71B | $26.55B | $164.68B | $18.60B | $60.87B | $60.07B | $1.00M | $54.24B | $67.19B | $70.46B | $1.00M | $-1.00M | $-1.00M | $- | $46.56B | $49.40B | $63.86B | $51.92B | $48.91B | $53.66B |
| Total Non-Current Assets | $2.25T | $2.26T | $2.49T | $2.37T | $2.32T | $2.43T | $1.48T | $1.41T | $1.44T | $1.52T | $1.49T | $1.41T | $1.42T | $1.39T | $1.38T | $1.40T | $1.43T | $1.42T | $1.46T | $1.45T |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $3.45T | $3.46T | $3.74T | $3.57T | $3.37T | $3.54T | $2.80T | $2.46T | $2.51T | $2.58T | $2.48T | $2.33T | $2.36T | $2.26T | $2.25T | $2.27T | $2.30T | $2.24T | $2.26T | $2.32T |
| Account Payables | $204.31B | $161.17B | $173.15B | $185.19B | $150.43B | $147.25B | $138.44B | $140.24B | $134.24B | $146.53B | $152.22B | $130.74B | $136.89B | $111.57B | $108.45B | $124.78B | $111.00B | $113.51B | $132.65B | $171.95B |
| Short Term Debt | $329.85B | $307.26B | $549.60B | $487.22B | $407.18B | $416.56B | $309.00B | $75.00B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $344.11B |
| Tax Payables | $- | $- | $29.69B | $38.52B | $34.82B | $31.32B | $16.27B | $5.14B | $18.45B | $26.25B | $18.86B | $32.39B | $21.98B | $12.38B | $14.63B | $8.39B | $26.59B | $19.67B | $12.14B | $4.01B |
| Deferred Revenue | $- | $36.05B | $29.69B | $38.52B | $149.30B | $142.67B | $133.86B | $-88.55B | $- | $- | $- | $-157.73B | $- | $- | $- | $-136.10B | $- | $- | $- | $-326.00B |
| Other Current Liabilities | $618.40B | $588.89B | $591.70B | $574.79B | $561.29B | $567.13B | $527.78B | $505.66B | $553.22B | $588.63B | $569.46B | $524.28B | $439.10B | $430.82B | $458.49B | $459.20B | $498.25B | $483.75B | $502.88B | $285.05B |
| Total Current Liabilities | $1.15T | $1.09T | $1.37T | $1.29T | $1.15T | $1.16T | $991.49B | $726.03B | $705.90B | $761.41B | $740.54B | $687.41B | $597.98B | $554.77B | $581.58B | $592.37B | $635.85B | $616.93B | $647.67B | $798.71B |
| Long Term Debt | $585.51B | $730.67B | $548.82B | $518.49B | $563.47B | $573.87B | $50.00B | $50.00B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $72.37B |
| Deferred Revenue Non-Current | $- | $- | $105.76B | $70.76B | $133.75B | $133.01B | $131.94B | $-50.00B | $-4.38B | $-5.02B | $155.65B | $138.94B | $243.80B | $246.04B | $-308.00M | $-80.00B | $-1.25B | $-2.75B | $-2.82B | $-72.37B |
| Deferred Tax Liabilities Non-Current | $- | $23.62B | $45.07B | $51.35B | $70.01B | $92.67B | $6.54B | $6.05B | $6.03B | $6.10B | $6.20B | $5.82B | $10.62B | $9.37B | $8.18B | $18.16B | $18.23B | $13.95B | $20.80B | $27.66B |
| Other Non-Current Liabilities | $219.75B | $84.74B | $91.38B | $47.30B | $-55.52B | $-58.14B | $39.57B | $166.48B | $231.59B | $166.63B | $40.40B | $39.91B | $37.56B | $33.70B | $276.83B | $276.98B | $274.16B | $276.50B | $280.88B | $157.91B |
| Total Non-Current Liabilities | $805.26B | $839.04B | $685.26B | $687.89B | $711.71B | $741.42B | $228.05B | $222.53B | $237.62B | $172.73B | $202.25B | $184.68B | $291.98B | $289.12B | $285.01B | $295.14B | $292.39B | $290.45B | $301.68B | $230.28B |
| Other Liabilities | $- | $1.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $1.96T | $1.93T | $2.06T | $1.97T | $1.87T | $1.90T | $1.22T | $948.56B | $943.52B | $934.14B | $942.79B | $872.09B | $889.95B | $843.89B | $866.59B | $887.51B | $928.23B | $907.39B | $949.35B | $1.03T |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $1.13T | $- | $- | $- | $1.18T | $1.21T | $1.27T | $1.25T | $- | $- | $- | $- | $- | $- |
| Common Stock | $103.00B | $103.00B | $103.00B | $103.00B | $103.00B | $103.00B | $103.00B | $103.00B | $103.00B | $103.00B | $103.00B | $103.00B | $103.00B | $103.00B | $103.00B | $103.00B | $103.00B | $103.00B | $103.00B | $103.00B |
| Retained Earnings | $654.06B | $817.61B | $783.78B | $809.40B | $838.62B | $884.51B | $884.53B | $908.16B | $996.25B | $1.00T | $924.98B | $944.26B | $999.64B | $985.23B | $945.96B | $953.29B | $963.01B | $941.85B | $918.89B | $905.85B |
| Accumulated Other Comprehensive Income Loss | $590.22B | $463.70B | $645.60B | $533.30B | $412.80B | $504.10B | $444.72B | $340.64B | $313.61B | $386.12B | $355.40B | $247.51B | $200.13B | $166.46B | $171.91B | $265.45B | $132.14B | $114.64B | $115.03B | $109.99B |
| Other Total Stockholders Equity | $146.53B | $145.53B | $144.06B | $150.29B | $148.84B | $147.73B | $146.16B | $156.16B | $157.57B | $156.82B | $155.67B | $165.53B | $163.52B | $162.93B | $161.99B | $162.45B | $170.46B | $170.14B | $169.76B | $170.33B |
| Total Stockholders Equity | $1.49T | $1.53T | $1.68T | $1.60T | $1.50T | $1.64T | $1.58T | $1.51T | $1.57T | $1.65T | $1.54T | $1.46T | $1.47T | $1.42T | $1.38T | $1.39T | $1.37T | $1.33T | $1.31T | $1.29T |
| Total Equity | $1.49T | $1.53T | $1.68T | $1.60T | $1.50T | $1.64T | $1.58T | $1.51T | $1.57T | $1.65T | $1.54T | $1.46T | $1.47T | $1.42T | $1.38T | $1.39T | $1.37T | $1.33T | $1.31T | $1.29T |
| Total Liabilities and Stockholders Equity | $3.45T | $3.46T | $3.74T | $3.57T | $3.37T | $3.54T | $2.80T | $2.46T | $2.51T | $2.58T | $2.48T | $2.33T | $2.36T | $2.26T | $2.25T | $2.27T | $2.30T | $2.24T | $2.26T | $2.32T |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $3.45T | $3.46T | $3.74T | $3.57T | $3.37T | $3.54T | $2.80T | $2.46T | $2.51T | $2.58T | $2.48T | $2.33T | $2.36T | $2.26T | $2.25T | $2.27T | $2.30T | $2.24T | $2.26T | $2.32T |
| Total Investments | $19.15B | $143.12B | $19.48B | $144.42B | $117.21B | $118.64B | $110.50B | $110.58B | $102.70B | $102.27B | $106.02B | $101.88B | $104.31B | $95.67B | $99.57B | $102.97B | $118.00B | $91.29B | $86.87B | $78.96B |
| Total Debt | $915.36B | $927.50B | $992.66B | $1.01T | $870.98B | $889.61B | $359.00B | $200.01B | $148.74B | $82.39B | $111.62B | $212.74B | $201.53B | $204.84B | $201.36B | $278.26B | $1.25B | $2.75B | $2.82B | $398.37B |
| Net Debt | $735.50B | $634.50B | $689.73B | $670.03B | $617.00B | $555.62B | $-202.49B | $-176.83B | $-233.08B | $-278.68B | $-201.39B | $-103.24B | $-148.68B | $-113.46B | $-100.56B | $-47.86B | $-305.27B | $-283.99B | $-237.11B | $79.98B |
Annual Cash Flow
| Breakdown | March 31, 2024 | March 31, 2023 | March 31, 2022 | March 31, 2021 | March 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $17.05B | $132.36B | $156.89B | $145.32B | $245.35B |
| Depreciation and Amortization | $157.84B | $105.74B | $79.68B | $72.65B | $66.40B |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $- | $- | $- | $- | $- |
| Change in Working Capital | $-51.70B | $-24.21B | $5.96B | $-31.73B | $-43.79B |
| Accounts Receivables | $-55.95B | $-4.85B | $-8.00B | $22.16B | $-16.39B |
| Inventory | $-60.04B | $-7.09B | $24.06B | $-2.32B | $-6.04B |
| Accounts Payables | $29.47B | $-12.27B | $-10.10B | $-51.57B | $-21.36B |
| Other Working Capital | $34.82B | $98.19B | $-16.64B | $47.39B | $-10.40B |
| Other Non Cash Items | $49.29B | $113.88B | $14.92B | $120.59B | $-45.96B |
| Net Cash Provided by Operating Activities | $172.47B | $327.77B | $257.44B | $306.84B | $222.00B |
| Investments in Property Plant and Equipment | $-38.06B | $-88.54B | $-76.45B | $-77.44B | $-77.89B |
| Acquisitions Net | $-784.97B | $- | $-670.00M | $-14.92B | $-320.76B |
| Purchases of Investments | $- | $- | $-5.58B | $- | $- |
| Sales Maturities of Investments | $- | $12.62B | $5.58B | $- | $- |
| Other Investing Activities | $-22.77B | $-8.58B | $14.71B | $10.46B | $8.86B |
| Net Cash Used for Investing Activities | $-845.80B | $-84.50B | $-62.41B | $-81.89B | $-389.79B |
| Debt Repayment | $771.23B | $-15.00B | $-60.00B | $-126.00B | $326.00B |
| Common Stock Issued | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-10.73B | $-60.56B | $-50.72B | $-9.16B | $-52.90B |
| Dividends Paid | $-116.65B | $-100.36B | $-85.24B | $-76.16B | $-73.54B |
| Other Financing Activities | $-29.79B | $-19.71B | $-20.34B | $-18.16B | $-18.51B |
| Net Cash Used Provided by Financing Activities | $614.06B | $-195.62B | $-216.30B | $-229.48B | $181.06B |
| Effect of Forex Changes on Cash | $18.11B | $13.21B | $11.12B | $12.27B | $-5.94B |
| Net Change in Cash | $-41.15B | $60.85B | $-10.14B | $7.74B | $7.32B |
| Cash at End of Period | $335.69B | $376.84B | $315.99B | $326.13B | $318.39B |
| Cash at Beginning of Period | $376.84B | $315.99B | $326.13B | $318.39B | $311.07B |
| Operating Cash Flow | $172.47B | $327.77B | $257.44B | $306.84B | $222.00B |
| Capital Expenditure | $-82.50B | $-88.54B | $-76.45B | $-77.44B | $-77.89B |
| Free Cash Flow | $89.98B | $239.23B | $181.00B | $229.40B | $144.11B |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-97.66B | $35.91B | $37.60B | $-33.28B | $21.45B | $5.33B | $46.85B | $-47.88B | $59.76B | $88.80B | $31.68B | $-10.52B | $78.32B | $53.26B | $35.83B | $-18.90B | $75.14B | $28.85B | $60.24B | $6.17B |
| Depreciation and Amortization | $51.16B | $50.02B | $50.27B | $48.64B | $46.98B | $38.97B | $23.24B | $23.02B | $23.00B | $22.85B | $36.87B | $21.08B | $21.52B | $18.94B | $18.14B | $18.56B | $18.15B | $17.94B | $18.00B | $18.10B |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Change in Working Capital | $-72.16B | $-14.13B | $-26.00B | $22.31B | $-26.17B | $-22.83B | $-41.55B | $27.42B | $-18.41B | $-3.02B | $-30.20B | $5.27B | $7.31B | $18.28B | $-24.90B | $23.61B | $-19.46B | $10.77B | $-46.65B | $29.31B |
| Accounts Receivables | $-51.64B | $-17.37B | $-26.79B | $-24.04B | $-25.61B | $-14.67B | $8.37B | $33.87B | $-24.74B | $2.77B | $-16.75B | $9.71B | $-4.45B | $6.74B | $-19.99B | $16.78B | $-12.48B | $31.09B | $-13.23B | $13.04B |
| Inventory | $-20.52B | $-16.97B | $790.00M | $-15.42B | $-15.99B | $-11.87B | $-16.76B | $-9.73B | $2.54B | $-4.00B | $4.11B | $6.80B | $1.84B | $7.17B | $8.26B | $-784.00M | $1.40B | $259.00M | $-3.20B | $-5.05B |
| Accounts Payables | $- | $2.79B | $-23.08B | $43.49B | $15.43B | $3.71B | $-33.17B | $3.29B | $3.79B | $-1.79B | $-17.57B | $-11.23B | $9.92B | $4.37B | $-13.16B | $7.62B | $- | $- | $- | $- |
| Other Working Capital | $- | $17.43B | $-2.96B | $18.28B | $14.55B | $20.97B | $-18.99B | $64.46B | $27.84B | $-13.77B | $19.67B | $-11.23B | $9.92B | $4.37B | $-33.15B | $24.40B | $-20.87B | $10.51B | $-43.45B | $34.36B |
| Other Non Cash Items | $134.68B | $-4.50B | $-49.27B | $130.14B | $9.15B | $15.41B | $-16.35B | $113.03B | $7.97B | $-17.61B | $10.48B | $32.75B | $-37.67B | $8.83B | $11.01B | $58.43B | $36.36B | $35.80B | $-9.99B | $-1.87B |
| Net Cash Provided by Operating Activities | $16.03B | $67.29B | $12.60B | $74.55B | $51.41B | $36.88B | $12.20B | $115.59B | $72.32B | $91.03B | $48.83B | $48.59B | $69.47B | $99.30B | $40.08B | $81.70B | $110.18B | $93.36B | $21.60B | $51.71B |
| Investments in Property Plant and Equipment | $2.29B | $-16.64B | $-14.00B | $-19.92B | $-15.27B | $-30.94B | $-16.36B | $-28.12B | $-20.73B | $-21.43B | $-18.26B | $-17.27B | $-11.30B | $-27.96B | $-19.91B | $-18.58B | $-15.82B | $-9.78B | $-33.26B | $-21.31B |
| Acquisitions Net | $- | $- | $- | $-190.00M | $-24.73B | $-760.05B | $- | $- | $- | $- | $- | $-11.00M | $-10.00M | $-1.00M | $-648.00M | $-13.00M | $-13.20B | $-40.00M | $-1.67B | $-307.85B |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $456.00M | $64.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-33.02B | $-2.22B | $-25.35B | $-8.25B | $-309.00M | $19.96B | $4.06B | $4.94B | $-6.45B | $5.91B | $-885.00M | $2.46B | $10.91B | $-26.52B | $-525.00M | $4.43B | $-433.00M | $-136.00M | $6.60B | $13.75B |
| Net Cash Used for Investing Activities | $-30.72B | $-18.86B | $-39.35B | $-24.73B | $-40.31B | $-771.03B | $-12.30B | $-22.72B | $-27.12B | $-15.52B | $-19.14B | $-14.83B | $8.16B | $-34.66B | $-21.09B | $-14.16B | $-29.45B | $-9.96B | $-28.33B | $-315.41B |
| Debt Repayment | $-15.57B | $-51.11B | $65.14B | $43.12B | $-17.23B | $511.35B | $234.00B | $-50.00B | $50.00B | $-30.00B | $15.00B | $-20.00B | $- | $-40.00B | $- | $-45.00B | $-19.00B | $-32.00B | $-30.00B | $- |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-1.00M | $-1.00M | $-6.96B | $-1.00M | $-2.00M | $-1.00M | $-10.73B | $-50.00B | $-2.00M | $- | $-10.55B | $-50.00B | $-1.00M | $-2.00M | $-713.00M | $-8.28B | $-1.00M | $-1.00M | $-880.00M | $-14.84B |
| Dividends Paid | $-66.23B | $- | $-62.76B | $- | $-62.75B | $- | $-53.90B | $- | $-54.68B | $- | $-45.68B | $- | $-46.32B | $- | $-38.91B | $- | $-39.01B | $- | $-37.15B | $- |
| Other Financing Activities | $-22.49B | $-3.23B | $-7.34B | $-12.19B | $-7.04B | $-6.23B | $-4.33B | $-4.50B | $-5.01B | $-4.83B | $-5.37B | $-5.03B | $-5.00B | $-5.20B | $-5.10B | $-4.86B | $-3.59B | $-4.76B | $-4.95B | $321.13B |
| Net Cash Used Provided by Financing Activities | $-104.30B | $-54.34B | $-11.92B | $30.93B | $-87.03B | $505.12B | $165.04B | $-104.50B | $-9.69B | $-34.83B | $-46.60B | $-75.03B | $-51.33B | $-45.21B | $-44.73B | $-58.14B | $-61.60B | $-36.76B | $-72.98B | $306.29B |
| Effect of Forex Changes on Cash | $5.87B | $-4.02B | $5.91B | $957.00M | $-4.09B | $1.54B | $19.71B | $6.65B | $-14.76B | $7.38B | $13.94B | $7.05B | $5.62B | $-3.06B | $1.52B | $10.21B | $648.00M | $154.00M | $1.25B | $-1.80B |
| Net Change in Cash | $179.87B | $-9.94B | $-32.76B | $81.71B | $-80.02B | $-227.49B | $184.65B | $-4.98B | $20.74B | $48.06B | $-2.97B | $-34.23B | $31.92B | $16.38B | $-24.21B | $19.61B | $19.78B | $46.80B | $-78.46B | $40.79B |
| Cash at End of Period | $179.87B | $292.99B | $302.93B | $335.69B | $253.98B | $333.99B | $561.49B | $376.84B | $381.82B | $361.07B | $313.01B | $315.99B | $350.21B | $318.30B | $301.92B | $326.13B | $306.51B | $286.73B | $239.93B | $318.39B |
| Cash at Beginning of Period | $- | $302.93B | $335.69B | $253.98B | $333.99B | $561.49B | $376.84B | $381.82B | $361.07B | $313.01B | $315.99B | $350.21B | $318.30B | $301.92B | $326.13B | $306.51B | $286.73B | $239.93B | $318.39B | $277.60B |
| Operating Cash Flow | $16.03B | $67.29B | $12.60B | $74.55B | $51.41B | $36.88B | $12.20B | $115.59B | $72.32B | $91.03B | $48.83B | $48.59B | $69.47B | $99.30B | $40.08B | $81.70B | $110.18B | $93.36B | $21.60B | $51.71B |
| Capital Expenditure | $2.29B | $-15.60B | $-14.00B | $-19.92B | $-15.27B | $-30.94B | $-16.36B | $-28.12B | $-20.73B | $-21.43B | $-18.26B | $-17.27B | $-11.30B | $-27.96B | $-19.91B | $-18.58B | $-15.82B | $-9.78B | $-33.26B | $-21.31B |
| Free Cash Flow | $18.32B | $51.69B | $-1.40B | $54.63B | $36.14B | $5.94B | $-4.17B | $87.47B | $51.58B | $69.59B | $30.57B | $31.31B | $58.17B | $71.34B | $20.17B | $63.12B | $94.36B | $83.58B | $-11.66B | $30.40B |
Astellas Pharma Dividends
Explore Astellas Pharma's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
3.96%
Dividend Payout Ratio
684.38%
Dividend Paid & Capex Coverage Ratio
0.87x
Astellas Pharma Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $37 | $37 | March 28, 2025 | March 31, 2025 | June 01, 2025 | |
| $37 | $37 | September 27, 2024 | September 30, 2024 | December 02, 2024 | |
| $35 | $35 | March 28, 2024 | March 31, 2024 | June 03, 2024 | |
| $35 | $35 | September 28, 2023 | September 30, 2023 | December 01, 2023 | |
| $30 | $30 | March 30, 2023 | March 31, 2023 | June 01, 2023 | |
| $30 | $30 | September 29, 2022 | September 30, 2022 | December 01, 2022 | |
| $25 | $25 | March 30, 2022 | March 31, 2022 | June 01, 2022 | |
| $25 | $25 | September 29, 2021 | September 30, 2021 | December 01, 2021 | |
| $21 | $21 | March 30, 2021 | March 31, 2021 | June 01, 2021 | |
| $21 | $21 | September 29, 2020 | September 30, 2020 | December 01, 2020 | |
| $20 | $20 | March 30, 2020 | March 31, 2020 | June 01, 2020 | |
| $20 | $20 | September 27, 2019 | September 30, 2019 | December 02, 2019 | |
| $19 | $19 | March 27, 2019 | March 31, 2019 | June 19, 2019 | |
| $19 | $19 | September 26, 2018 | September 30, 2018 | December 03, 2018 | |
| $18 | $18 | March 28, 2018 | March 31, 2018 | June 18, 2018 | |
| $18 | $18 | September 27, 2017 | September 30, 2017 | December 01, 2017 | |
| $17 | $17 | March 29, 2017 | March 31, 2017 | June 20, 2017 | |
| $17 | $17 | September 28, 2016 | |||
| $16 | $16 | March 29, 2016 | |||
| $16 | $16 | September 28, 2015 |
Astellas Pharma News
Read the latest news about Astellas Pharma, including recent articles, headlines, and updates.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for 4503.T.